Tag: jon klein
Klein named executive vice president for research and innovation
Jon Klein, a 40-year veteran of medical and higher education experience at the University of Louisville, has been named the university鈥檚 executive vice president...
UofL secures $24M to develop next generation of clinical researchers
The University of Louisville has secured $24 million to train the next generation of clinical researchers and drive work that can save and improve...
Research!Louisville closes with update on overdose crisis and awards presentation
The closing ceremonies for Research!Louisville (R!L) 2024 reached standing-room-only capacity with faculty, staff and student research scholars, administrators, sponsors and guests. University of Louisville...
STRONG MEDICINE: UofL鈥檚 unrivaled leadership infuses regional biomedical innovation
One step, then another, then another.聽聽聽
Suspended in a pediatric therapy harness, the boy鈥檚 feet moved across the treadmill. Each foot strike represented new hope...
UofL receives $3M to further biomedical research Gift marks more than...
The University of Louisville has received $3 million to enhance its research infrastructure and help further groundbreaking work that can save and improve lives.
The...
UofL researchers honored for groundbreaking study linking cancer and kidney disease
A team of researchers at the University of Louisville has been honored for their pioneering work in uncovering a new connection between cancer treatment...
UofL innovators selected for inaugural National Academy of Inventors honor
Four University of Louisville innovators have been selected by the prestigious National Academy of Inventors (NAI) for its 2024 class of Senior聽Members.聽
NAI Senior Members...
UofL researchers among the most-cited in the world
More than 100 University of Louisville researchers are among the top 2% most-cited in the world, according to a new list compiled by Stanford...
UofL doctor is a participant in Pfizer’s COVID-19 vaccine trial
Pharmaceutical company Pfizer and its collaborator, BioNTech, announced today that early results in a Phase 3 clinical trial show their COVID-19 vaccine candidate is...